Filtros de búsqueda

Lista de obras de

2503. Differences Between Experts and Community Clinicians in Selecting HIV Switch Regimens for Patients With Viral Suppression

artículo científico publicado en 2019

2510. Systematic Literature Review of Multiclass Resistance in Heavily Treatment Experienced Persons with HIV

scholarly article by Josephine Mauskopf et al published 23 October 2019 in Open Forum Infectious Diseases

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults

article

550. Adherence and Persistency With Modern Single vs. Multi-Tablet Antiretroviral (ARV) Regimens in First Treatment of HIV in Clinical Practice

article

A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination.

artículo científico publicado en 2017

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

artículo científico publicado en 2013

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 result

artículo científico publicado en 2014

A single case of cure?

artículo científico publicado en 2008

ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL.

artículo científico publicado en 2017

AZT or tenofovir for patients with the K65R mutation?

artículo científico publicado en 2010

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

artículo científico publicado en 2009

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

artículo científico publicado en 2011

Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents

artículo científico publicado en 2009

Advances in HIV therapeutics: the 14th CROI

artículo científico publicado en 2007

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel

scientific article published on July 2016

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel

artículo científico publicado en 2018

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel

artículo científico publicado en 2020

Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers

artículo científico publicado en 2020

Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection ⬇️

artículo científico publicado el 2 de mayo de 2003

Antiretroviral therapy for treatment-naïve patients: a review of recent literature and the updated guidelines

artículo científico publicado en 2009

Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meeting.

artículo científico publicado en 2009

Antiretroviral treatment update from the 17th International AIDS Conference.

artículo científico publicado en 2008

Assessing the performance of a computer-based policy model of HIV and AIDS

artículo científico publicado en 2010

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data

artículo científico publicado en 2014

Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System ⬇️

artículo científico publicado el 15 de diciembre de 2010

Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202

scientific article published on February 2014

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

artículo científico publicado en 2011

Atypical Skeletal Muscle Profiles in HIV+ Asymptomatic Middle-Aged Adults

artículo científico publicado en 2017

Beginning antiretroviral therapy for patients with HIV.

artículo científico publicado en 2014

Beta-glucan for Pneumocystis pneumonia diagnosis in persons with AIDS: authors' reply.

artículo científico publicado en 2013

Beyond efficacy: the impact of combination antiretroviral therapy on quality of life

artículo científico publicado en 2005

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial

artículo científico publicado en 2017

Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia.

artículo científico publicado en 2011

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

artículo científico publicado en 2011

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events

artículo científico publicado en 2018

Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results

artículo científico publicado en 2016

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results

artículo científico publicado en 2017

Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

artículo científico publicado en 2012

Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine

artículo científico publicado en 2014

Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19

scientific article published on 09 September 2020

Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States

scientific article published on 01 March 2020

Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States

artículo científico publicado en 2020

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non

artículo científico publicado en 2019

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

artículo científico publicado en 2012

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inf

artículo científico publicado en 2017

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide

Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study

artículo científico publicado en 2013

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.

artículo científico publicado en 2017

Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease

artículo científico publicado en 2012

Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults

artículo científico publicado en 2002

Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development

artículo científico publicado en 2012

Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease

artículo científico publicado en 2005

Cost-effectiveness of genotype testing for primary resistance in Brazil

artículo científico publicado en 2015

Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications

artículo científico publicado en 2003

Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial

artículo científico publicado en 2014

Darunavir now approved for use in treatment-naive patients.

artículo científico publicado en 2008

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353

scientific article published in 2019

Dolutegravir plus lamivudine maintain HIV-1 suppression through week 48 in a pilot randomized trial.

artículo científico publicado en 2017

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

artículo científico publicado en 2018

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

artículo científico publicado en 2019

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferi

artículo científico publicado en 2020

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

scientific article published on 01 February 2019

Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164

artículo científico publicado en 2010

Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.

artículo científico publicado en 2013

Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States

artículo científico publicado en 2013

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants

artículo científico publicado en 2017

Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview

artículo científico publicado en 2004

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials

artículo científico publicado en 2016

Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases

artículo científico publicado en 2020

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy

artículo científico publicado en 2008

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority

artículo científico publicado en 2020

Fragility Fractures in HIV-Infected Patients: Need for Better Understanding of Diagnosis and Management

article

Gender disparities in COVID-19 clinical trial leadership

artículo científico publicado en 2021

Gender disparities in international COVID-19 clinical trial leadership

preprint

Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights

scientific article published on 26 February 2018

Genital HIV-1 Shedding with Dolutegravir (DTG) plus Lamivudine (3TC) Dual Therapy

article

HIV and syphilis coinfection: trends and interactions

article

HIV cure strategies: how good must they be to improve on current antiretroviral therapy?

artículo científico publicado en 2014

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness

artículo científico publicado en 2009

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status

artículo científico publicado en 2012

HSV-1 encephalitis complicated by cerebral hemorrhage in an HIV-positive person.

artículo científico publicado en 2009

Health Considerations for HIV-Infected International Travelers

scientific article published on 12 April 2019

Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients

artículo científico publicado en 2006

Hiv Controllers Maintain Viral Suppression Despite Waning T-Cell Responses On Art

artículo científico publicado en 2020

Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation

artículo científico publicado en 2020

Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study

artículo científico publicado en 2017

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202

artículo científico publicado en 2012

Impact of randomized antiretroviral therapy initiation on glucose metabolism

artículo científico publicado en 2014

Improving on effective antiretroviral therapy: how good will a cure have to be?

artículo científico publicado en 2016

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

artículo científico publicado en 2012

Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals

artículo científico publicado en 2003

LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial

article

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

artículo científico publicado en 2015

Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection

artículo científico publicado en 2006

Low Prevalence of Ongoing Hepatitis B Viremia in HIV-Positive Individuals with Isolated Antibody to Hepatitis B Core Antigen ⬇️

artículo científico publicado el 1 de diciembre de 2003

Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials

artículo científico publicado en 2014

Male sexual dysfunction associated with antiretroviral therapy

artículo científico publicado en 2002

Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full?

artículo científico publicado en 2010

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

artículo científico publicado en 2000

Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age

artículo científico publicado en 2012

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks

artículo científico publicado en 2012

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

artículo científico publicado en 2004

Middle-Aged Men With HIV Have Diminished Accelerometry-Based Activity Profiles Despite Similar Lab-Measured Gait Speed: Pilot Study

article

Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial

artículo científico publicado en 2020

No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial

artículo científico publicado en 2019

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

artículo científico publicado en 2016

Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series

scientific article published on 09 September 2020

Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis

artículo científico publicado en 2020

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

artículo científico publicado en 2013

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s

artículo científico publicado en 2011

Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases

artículo científico publicado en 2008

Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial

artículo científico publicado en 2007

Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy

artículo científico publicado en 2013

Predicting virologic failure in an HIV clinic

artículo científico publicado en 2010

Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution

scientific article published on 20 March 2003

Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma

artículo científico publicado en 2004

Preventing and treating HIV-related OIs--updated guidelines

article

Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion

artículo científico publicado en 2014

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy

scientific article published on 09 March 2020

Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US

artículo científico publicado en 2015

Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US

article

Projected survival gains from revising state laws requiring written opt-in consent for HIV testing.

artículo científico publicado en 2011

Projecting 10-yr, 20-yr and Lifetime Risks of Cardiovascular Disease in Persons Living with HIV in the US.

artículo científico publicado en 2017

Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection

artículo científico publicado en 2003

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202

article

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.

artículo científico publicado en 2017

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

article

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

artículo científico publicado en 2017

Rapid fingerstick testing: a new era in HIV diagnostics

article

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV

scientific article published on 13 February 2020

Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s

artículo científico publicado en 2015

Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy

artículo científico publicado en 2019

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials

artículo científico publicado en 2019

Renal safety of tenofovir disoproxil fumarate.

artículo científico publicado en 2007

Repeat hepatitis B vaccination may lead to seroprotection in HIV-infected patients who do not respond to an initial series

artículo científico publicado en 2009

Report from the 15th Retrovirus Conference. Etravirine resistance: baseline prevalence and proposed criteria for "vircotype".

artículo científico publicado en 2008

Report from the 16th Conference on Retroviruses and Opportunistic Infections. Concomitant HIV/TB treatment improves survival

article

Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine

artículo científico publicado en 2010

Report from the 2008 joint ICAAC/IDSA meeting. Bevirimat: predictors of response.

artículo científico publicado en 2008

Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.

artículo científico publicado en 2008

Report from the 2008 joint ICAAC/IDSA meeting. Early ART and overall survival

artículo científico publicado en 2008

Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT.

artículo científico publicado en 2008

Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC.

artículo científico publicado en 2008

Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients

artículo científico publicado en 2008

Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention

article

Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again

article

Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study

article

Report from the Tenth Retrovirus Conference. New drugs

artículo científico publicado el 1 de abril de 2003

Report on the XIV International AIDS Conference.

artículo científico publicado en 2002

Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies

artículo científico publicado en 2005

Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study

scientific article published on 02 April 2019

Roundtable. Who should be providing HIV care?

article

Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.

artículo científico publicado en 2005

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

artículo científico publicado en 2002

Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection ⬇️

artículo científico publicado en 2010

Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.

artículo científico publicado en 2009

Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa

artículo científico publicado en 2017

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

artículo científico publicado en 2014

Short and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study

artículo científico publicado en 2015

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis

artículo científico publicado en 2005

Should we be testing for baseline integrase resistance in patients newly diagnosed with HIV?

artículo científico publicado en 2017

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

artículo científico publicado en 2020

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

artículo científico publicado en 2015

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

artículo científico publicado en 2014

Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms

artículo científico publicado en 2013

The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States

artículo científico publicado en 2017

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

artículo científico publicado en 2015

The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States

artículo científico publicado en 2006

The clinical role and cost-effectiveness of long-acting antiretroviral therapy

artículo científico publicado en 2015

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

artículo científico publicado en 2008

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

artículo científico publicado en 2010

The survival benefits of AIDS treatment in the United States

artículo científico publicado en 2006

Top stories of 2008. Newer drugs strikingly effective when given together

artículo científico publicado en 2009

Transcriptional Changes during Naturally Acquired Zika Virus Infection Render Dendritic Cells Highly Conducive to Viral Replication.

artículo científico publicado en 2017

Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors

scientific article published on 17 September 2020

Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care.

artículo científico publicado en 2005

Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy

artículo científico publicado en 2002

Treatment-for-prevention: clinical considerations

artículo científico

Untreated HIV: harmful even at high CD4 cell counts

artículo científico publicado en 2010

Update on antiretroviral therapy: the 15th CROI.

scientific article published on May 2008

Use of a serum beta-glucan assay for diagnosis of HIV-related Pneumocystis jiroveci pneumonia in patients with negative microscopic examination results

artículo científico publicado en 2008

Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA ≥1,000,000 copies/ml: a post hoc analysis of Phase III clinical trials

artículo científico publicado en 2017

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

artículo científico publicado en 2019

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density

scientific article published on August 2013

When to start antiretroviral therapy--ready when you are?

artículo científico publicado en 2009

XVI International AIDS Conference: Part 1

scientific article published on 01 October 2006

XVI International AIDS Conference: Part 2

artículo científico publicado en 2006

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda